Source: Investor’s Business Daily
Novavax (NVAX) said Monday it’s planning to begin the U.S.-based study of its coronavirus vaccine “in the coming weeks.” NVAX stock popped on the news.
Previously, Novavax said it expected to begin Phase 3 testing in the U.S. in November. Now, the biotech company says studies in the U.S. and Mexico will begin “in the coming weeks.” NVAX stock initially fell on the news. Novavax is currently working to iron out manufacturing for its vaccine in North Carolina.
It was the second big hang-up for the biotech company’s vaccine to combat Covid-19. The Phase 3 test in the U.S. and Mexico was originally expected to begin in mid-October. Then, the company pushed the start date out to the end of November.